Imaging Treatment Response with Hyperpolarized Pyruvate in Anaplastic Thyroid Carcinoma
Christopher M Walker1, Zhan Xu1, Keith Michel1, Gary Martinez1, Collin J. Harlan1, Jeremy W. Gordon2, Stephanie Carlon1, Sandra Williams1, Freddy Gonzalez1, Stacy Hash1, Jerell Jones1, Asa McCoy1, Brandy Willis1, Michelle Underwood1, Andrew Day3, Moin Chariwala3, Dao Le4, Gregory Waligorski3, Daniel B. Vigneron2, Dawid Schellingerhout5, Stephen Y. Lai6, and James A. Bankson1
1Imaging Physics, MD Anderson Cancer Center, Houston, TX, United States, 22. Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, San Francisco, CA, United States, 3Center for Advanced Biomedical Imaging, MD Anderson Cancer Center, Houston, TX, United States, 4Nuclear Medicine, MD Anderson Cancer Center, Houston, TX, United States, 5Nueroradiology, MD Anderson Cancer Center, Houston, TX, United States, 6Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, United States
We present a decrease in the conversion of hyperpolarized pyruvate
into lactate production following eight days of systemic therapy in a patient
with anaplastic thyroid cancer.
nLac
maps overlaid on top of T2w images at baseline (left) or 8 days
into systemic treatment (right). All high nLac voxels were confined to the
tumor. Measured nLac values were reduced 31% 8 days after the onset of
systemic therapy.
Baseline area under the curve images for hyperpolarized
pyruvate (left) and lactate (right) overlaid on top of T2w images of
a large left-sided ATC tumor identified with the white arrows on slice 2. Pyruvate
signal is primarily observed in the vascular anatomy while lactate signal is
localized to the tumor.